drugset
drugset / Trial / NCT06299826

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

NCT06299826 ↗

Phase 2 Completed 375 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in participants with chronic heart failure (HF).

Timeline

Start
2024-06-04
Primary completion
2026-02-10
Completion
2026-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5462 Unknown — Oral

Indications

heart failure